Glycans and Glycan-Binding Proteins in Atherosclerosis

Veit Eckardt; Christian Weber; Philipp von Hundelshausen

doi:10.1055/s-0039-1692720

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2019; 119(08): 1265-1273
DOI: 10.1055/s-0039-1692720

Theme Issue Article

Georg Thieme Verlag KG Stuttgart · New York

Glycans and Glycan-Binding Proteins in Atherosclerosis

Authors

Veit Eckardt

¹Institute for Cardiovascular Prevention, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany
Christian Weber

¹Institute for Cardiovascular Prevention, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany

²German Centre for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany
Philipp von Hundelshausen

¹Institute for Cardiovascular Prevention, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany

²German Centre for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany

Abstract

Complex glycans are readily accessible on the endothelium and on cell and plasma components. They interact with glycan-binding proteins which translate their structure into function. Advanced analytical tools are available to investigate their structure and functional interactions. Modifications to glycan structures which alter their capacity to bind proteins are particularly relevant in atherosclerosis. We summarize the regulatory role of glycans and their binding partners in the development of the disease. Given their complexity, accessibility, and important functional role, glycans and glycan-binding proteins represent promising diagnostic tools and therapeutic targets.

Keywords

glycocalyx - glycosaminoglycan - chemokine - selectin - galectin - low-density lipoprotein

Full Text

References

References
1 Rakus JF, Mahal LK. New technologies for glycomic analysis: toward a systematic understanding of the glycome. Annu Rev Anal Chem (Palo Alto, Calif) 2011; 4: 367-392
2 Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell 2006; 126 (05) 855-867
3 Landsteiner K. Ueber Agglutinationserscheinungen normalen menschlichen Blutes. Wien Klin Wochenschr 1901; 46: 1132-1134
4 Watkins WM, Morgan WTJ. Neutralization of the anti-H agglutinin in eel serum by simple sugars. Nature 1952; 169 (4307): 825-826
5 Watkins WM, Morgan WTJ. Inhibition by simple sugars of enzymes which decompose the blood-group substances. Nature 1955; 175 (4459): 676-677
6 Schunkert H, König IR, Kathiresan S. , et al; Cardiogenics; CARDIoGRAM Consortium. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011; 43 (04) 333-338
7 Teslovich TM, Musunuru K, Smith AV. , et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466 (7307): 707-713
8 Reilly MP, Li M, He J. , et al; Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011; 377 (9763): 383-392
9 Zhong M, Zhang H, Reilly JP. , et al. ABO blood group as a model for platelet glycan modification in arterial thrombosis. Arterioscler Thromb Vasc Biol 2015; 35 (07) 1570-1578
10 Stillmark H. Ueber Ricin, ein giftiges Ferment aus den Samen von Ricinus comm. L. und einigen anderen Euphorbiaceen [M.D. dissertation]. Dorpat: Kaiserliche Universität zu Dorpat; 1888
11 Gabius H-J, Siebert H-C, André S, Jiménez-Barbero J, Rüdiger H. Chemical biology of the sugar code. ChemBioChem 2004; 5 (06) 740-764
12 Sharon N, Lis H. History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology 2004; 14 (11) 53R-62R
13 Lindahl U. Heparan sulfate-protein interactions--a concept for drug design?. Thromb Haemost 2007; 98 (01) 109-115
14 Petitou M, van Boeckel CAA. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?. Angew Chem Int Ed Engl 2004; 43 (24) 3118-3133
15 Mueller RL, Scheidt S. History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation 1994; 89 (01) 432-449
16 Marki A, Esko JD, Pries AR, Ley K. Role of the endothelial surface layer in neutrophil recruitment. J Leukoc Biol 2015; 98 (04) 503-515
17 Tarbell JM, Cancel LM. The glycocalyx and its significance in human medicine. J Intern Med 2016; 280 (01) 97-113
18 Taylor ME, Drickamer K, Schnaar RL, Etzler ME, Varki A. Discovery and classification of glycan-binding proteins. In: Varki A, Cummings RD, Esko JD. , et al, eds. Essentials of Glycobiology. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2015: 361-372
19 Cummings RD. The repertoire of glycan determinants in the human glycome. Mol Biosyst 2009; 5 (10) 1087-1104
20 Yang Y, Franc V, Heck AJR. Glycoproteomics: a balance between high-throughput and in-depth analysis. Trends Biotechnol 2017; 35 (07) 598-609
21 Palaniappan KK, Bertozzi CR. Chemical glycoproteomics. Chem Rev 2016; 116 (23) 14277-14306
22 Smith DF, Cummings RD. Application of microarrays for deciphering the structure and function of the human glycome. Mol Cell Proteomics 2013; 12 (04) 902-912
23 Hirabayashi J, Yamada M, Kuno A, Tateno H. Lectin microarrays: concept, principle and applications. Chem Soc Rev 2013; 42 (10) 4443-4458
24 Sieve I, Münster-Kühnel AK, Hilfiker-Kleiner D. Regulation and function of endothelial glycocalyx layer in vascular diseases. Vascul Pharmacol 2018; 100: 26-33
25 Scott DW, Patel RP. Endothelial heterogeneity and adhesion molecules N-glycosylation: implications in leukocyte trafficking in inflammation. Glycobiology 2013; 23 (06) 622-633
26 Aird WC. Spatial and temporal dynamics of the endothelium. J Thromb Haemost 2005; 3 (07) 1392-1406
27 Hahn C, Schwartz MA. Mechanotransduction in vascular physiology and atherogenesis. Nat Rev Mol Cell Biol 2009; 10 (01) 53-62
28 Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE. Regulation of protein function by glycosaminoglycans--as exemplified by chemokines. Annu Rev Biochem 2005; 74: 385-410
29 Weber C, Badimon L, Mach F, van der Vorst EPC. Therapeutic strategies for atherosclerosis and atherothrombosis: past, present and future. Thromb Haemost 2017; 117 (07) 1258-1264
30 Gisterå A, Hansson GK. The immunology of atherosclerosis. Nat Rev Nephrol 2017; 13 (06) 368-380
31 Reitsma S, Oude Egbrink MGA, Heijnen VVT. , et al. Endothelial glycocalyx thickness and platelet-vessel wall interactions during atherogenesis. Thromb Haemost 2011; 106 (05) 939-946
32 Massberg S, Brand K, Grüner S. , et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196 (07) 887-896
33 Nagy N, Freudenberger T, Melchior-Becker A. , et al. Inhibition of hyaluronan synthesis accelerates murine atherosclerosis: novel insights into the role of hyaluronan synthesis. Circulation 2010; 122 (22) 2313-2322
34 Reine TM, Kusche-Gullberg M, Feta A, Jenssen T, Kolset SO. Heparan sulfate expression is affected by inflammatory stimuli in primary human endothelial cells. Glycoconj J 2012; 29 (01) 67-76
35 Nieuwdorp M, Meuwese MC, Mooij HL. , et al. Tumor necrosis factor-α inhibition protects against endotoxin-induced endothelial glycocalyx perturbation. Atherosclerosis 2009; 202 (01) 296-303
36 Nieuwdorp M, Holleman F, de Groot E. , et al. Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis. Diabetologia 2007; 50 (06) 1288-1293
37 van den Berg BM, Spaan JAE, Vink H. Impaired glycocalyx barrier properties contribute to enhanced intimal low-density lipoprotein accumulation at the carotid artery bifurcation in mice. Pflugers Arch 2009; 457 (06) 1199-1206
38 Ori A, Wilkinson MC, Fernig DG. A systems biology approach for the investigation of the heparin/heparan sulfate interactome. J Biol Chem 2011; 286 (22) 19892-19904
39 Ricard-Blum S, Lisacek F. Glycosaminoglycanomics: where we are. Glycoconj J 2017; 34 (03) 339-349
40 Xu D, Esko JD. Demystifying heparan sulfate-protein interactions. Annu Rev Biochem 2014; 83: 129-157
41 Gerhardt T, Ley K. Monocyte trafficking across the vessel wall. Cardiovasc Res 2015; 107 (03) 321-330
42 Axelsson J, Xu D, Kang BN. , et al. Inactivation of heparan sulfate 2-O-sulfotransferase accentuates neutrophil infiltration during acute inflammation in mice. Blood 2012; 120 (08) 1742-1751
43 Wang L, Fuster M, Sriramarao P, Esko JD. Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 2005; 6 (09) 902-910
44 Koenen RR, von Hundelshausen P, Nesmelova IV. , et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009; 15 (01) 97-103
45 von Hundelshausen P, Koenen RR, Sack M. , et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005; 105 (03) 924-930
46 von Hundelshausen P, Agten SM, Eckardt V. , et al. Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation. Sci Transl Med 2017; 9 (384) eaah6650
47 Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002; 110 (01) 127-136
48 Rehm M, Bruegger D, Christ F. , et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation 2007; 116 (17) 1896-1906
49 Vigetti D, Genasetti A, Karousou E. , et al. Proinflammatory cytokines induce hyaluronan synthesis and monocyte adhesion in human endothelial cells through hyaluronan synthase 2 (HAS2) and the nuclear factor-kappaB (NF-kappaB) pathway. J Biol Chem 2010; 285 (32) 24639-24645
50 Homann S, Grandoch M, Kiene LS. , et al. Hyaluronan synthase 3 promotes plaque inflammation and atheroprogression. Matrix Biol 2018; 66: 67-80
51 Grandoch M, Bollyky PL, Fischer JW. Hyaluronan: a master switch between vascular homeostasis and inflammation. Circ Res 2018; 122 (10) 1341-1343
52 Skålén K, Gustafsson M, Rydberg EK. , et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417 (6890): 750-754
53 Gustafsen C, Olsen D, Vilstrup J. , et al. Heparan sulfate proteoglycans present PCSK9 to the LDL receptor. Nat Commun 2017; 8 (01) 503
54 Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005; 96 (06) 612-616
55 Coenen DM, Mastenbroek TG, Cosemans JMEM. Platelet interaction with activated endothelium: mechanistic insights from microfluidics. Blood 2017; 130 (26) 2819-2828
56 McEver RP. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc Res 2015; 107 (03) 331-339
57 Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008; 111 (11) 5271-5281
58 Sperandio M, Gleissner CA, Ley K. Glycosylation in immune cell trafficking. Immunol Rev 2009; 230 (01) 97-113
59 Eriksson EE, Xie X, Werr J, Thoren P, Lindbom L. Importance of primary capture and L-selectin-dependent secondary capture in leukocyte accumulation in inflammation and atherosclerosis in vivo. J Exp Med 2001; 194 (02) 205-218
60 Cambi A, Figdor CG. Dual function of C-type lectin-like receptors in the immune system. Curr Opin Cell Biol 2003; 15 (05) 539-546
61 Sperandio M, Smith ML, Forlow SB. , et al. P-selectin glycoprotein ligand-1 mediates L-selectin-dependent leukocyte rolling in venules. J Exp Med 2003; 197 (10) 1355-1363
62 Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood 2011; 118 (26) 6743-6751
63 An G, Wang H, Tang R. , et al. P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice. Circulation 2008; 117 (25) 3227-3237
64 Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, Wagner DD. The combined role of P- and E-selectins in atherosclerosis. J Clin Invest 1998; 102 (01) 145-152
65 Quach ME, Chen W, Li R. Mechanisms of platelet clearance and translation to improve platelet storage. Blood 2018; 131 (14) 1512-1521
66 Wandall HH, Rumjantseva V, Sørensen AL. , et al. The origin and function of platelet glycosyltransferases. Blood 2012; 120 (03) 626-635
67 Sørensen AL, Rumjantseva V, Nayeb-Hashemi S. , et al. Role of sialic acid for platelet life span: exposure of β-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood 2009; 114 (08) 1645-1654
68 Grewal PK, Uchiyama S, Ditto D. , et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 2008; 14 (06) 648-655
69 Ward SE, O'Sullivan JM, Drakeford C. , et al. A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance. Blood 2018; 131 (08) 911-916
70 Li Y, Fu J, Ling Y. , et al. Sialylation on O-glycans protects platelets from clearance by liver Kupffer cells. Proc Natl Acad Sci U S A 2017; 114 (31) 8360-8365
71 Nioi P, Sigurdsson A, Thorleifsson G. , et al. Variant ASGR1 associated with a reduced risk of coronary artery disease. N Engl J Med 2016; 374 (22) 2131-2141
72 Yang A, Gyulay G, Mitchell M, White E, Trigatti BL, Igdoura SA. Hypomorphic sialidase expression decreases serum cholesterol by downregulation of VLDL production in mice. J Lipid Res 2012; 53 (12) 2573-2585
73 Bartlett AL, Grewal T, De Angelis E, Myers S, Stanley KK. Role of the macrophage galactose lectin in the uptake of desialylated LDL. Atherosclerosis 2000; 153 (01) 219-230
74 Ray KK, Landmesser U, Leiter LA. , et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 2017; 376 (15) 1430-1440
75 Nair JK, Willoughby JLS, Chan A. , et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 2014; 136 (49) 16958-16961
76 Pothineni NVK, Karathanasis SK, Ding Z, Arulandu A, Varughese KI, Mehta JL. LOX-1 in atherosclerosis and myocardial ischemia: biology, genetics, and modulation. J Am Coll Cardiol 2017; 69 (22) 2759-2768
77 Chen M, Kakutani M, Naruko T. , et al. Activation-dependent surface expression of LOX-1 in human platelets. Biochem Biophys Res Commun 2001; 282 (01) 153-158
78 Chatterjee M, Rath D, Schlotterbeck J. , et al. Regulation of oxidized platelet lipidome: implications for coronary artery disease. Eur Heart J 2017; 38 (25) 1993-2005
79 Hayashida K, Kume N, Murase T. , et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation 2005; 112 (06) 812-818
80 Matthijsen RA, de Winther MPJ, Kuipers D. , et al. Macrophage-specific expression of mannose-binding lectin controls atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009; 119 (16) 2188-2195
81 Saevarsdottir S, Oskarsson OO, Aspelund T. , et al. Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk. J Exp Med 2005; 201 (01) 117-125
82 Varki A, Schnaar RL, Crocker PR. I-type lectins. In: Varki A, Cummings RD, Esko JD. , et al, eds. Essentials of Glycobiology. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2015: 453-467
83 Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7 (09) 678-689
84 Xiong Y-S, Wu A-L, Lin Q-S. , et al. Contribution of monocytes Siglec-1 in stimulating T cells proliferation and activation in atherosclerosis. Atherosclerosis 2012; 224 (01) 58-65
85 Xiong Y-S, Wu A-L, Mu D. , et al. Inhibition of siglec-1 by lentivirus mediated small interfering RNA attenuates atherogenesis in apoE-deficient mice. Clin Immunol 2017; 174: 32-40
86 Xiong Y-S, Zhou Y-H, Rong G-H. , et al. Siglec-1 on monocytes is a potential risk marker for monitoring disease severity in coronary artery disease. Clin Biochem 2009; 42 (10-11): 1057-1063
87 Draude G, von Hundelshausen P, Frankenberger M, Ziegler-Heitbrock HW, Weber C. Distinct scavenger receptor expression and function in the human CD14(+)/CD16(+) monocyte subset. Am J Physiol 1999; 276 (04) H1144-H1149
88 Miller MC, Ludwig A-K, Wichapong K. , et al. Adhesion/growth-regulatory galectins tested in combination: evidence for formation of hybrids as heterodimers. Biochem J 2018; 475 (05) 1003-1018
89 Gabius H-J, Manning JC, Kopitz J, André S, Kaltner H. Sweet complementarity: the functional pairing of glycans with lectins. Cell Mol Life Sci 2016; 73 (10) 1989-2016
90 Stowell SR, Arthur CM, Mehta P. , et al. Galectin-1, -2, and -3 exhibit differential recognition of sialylated glycans and blood group antigens. J Biol Chem 2008; 283 (15) 10109-10123
91 Saint-Lu N, Oortwijn BD, Pegon JN. , et al. Identification of galectin-1 and galectin-3 as novel partners for von Willebrand factor. Arterioscler Thromb Vasc Biol 2012; 32 (04) 894-901
92 O'Sullivan JM, Jenkins PV, Rawley O. , et al. Galectin-1 and galectin-3 constitute novel-binding partners for factor VIII. Arterioscler Thromb Vasc Biol 2016; 36 (05) 855-863
93 Romaniuk MA, Croci DO, Lapponi MJ. , et al. Binding of galectin-1 to αIIbβ₃ integrin triggers “outside-in” signals, stimulates platelet activation, and controls primary hemostasis. FASEB J 2012; 26 (07) 2788-2798
94 Pacienza N, Pozner RG, Bianco GA. , et al. The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation. FASEB J 2008; 22 (04) 1113-1123
95 Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha. J Exp Med 1998; 187 (03) 329-339
96 Cattaneo V, Tribulatti MV, Carabelli J, Carestia A, Schattner M, Campetella O. Galectin-8 elicits pro-inflammatory activities in the endothelium. Glycobiology 2014; 24 (10) 966-973
97 Romaniuk MA, Tribulatti MV, Cattaneo V. , et al. Human platelets express and are activated by galectin-8. Biochem J 2010; 432 (03) 535-547
98 MacKinnon AC, Liu X, Hadoke PWF, Miller MR, Newby DE, Sethi T. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology 2013; 23 (06) 654-663
99 Papaspyridonos M, McNeill E, de Bono JP. , et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008; 28 (03) 433-440
100 Liu F-T, Hsu DK, Zuberi RI, Kuwabara I, Chi EY, Henderson Jr WR. Expression and function of galectin-3, a β-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol 1995; 147 (04) 1016-1028
101 Kim K, Mayer EP, Nachtigal M. Galectin-3 expression in macrophages is signaled by Ras/MAP kinase pathway and up-regulated by modified lipoproteins. Biochim Biophys Acta 2003; 1641 (01) 13-23
102 Zhu W, Sano H, Nagai R, Fukuhara K, Miyazaki A, Horiuchi S. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem Biophys Res Commun 2001; 280 (04) 1183-1188
103 Rong JX, Shapiro M, Trogan E, Fisher EA. Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl Acad Sci U S A 2003; 100 (23) 13531-13536
104 Nachtigal M, Ghaffar A, Mayer EP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol 2008; 172 (01) 247-255